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Trifluoperazine, the generic name for Stelazine, is a new phenothi-
azine derivative developed fo,r use as an anti-psychotic agent. The ear-
liest research with this drug appeared in the literature in 1958. 
On the basis of animal tests, Madgwick, McNeil!, and Driver (16) 
and Bordeleau and Gratton (2) reported that trifluoperazine has nine 
times the. potency of chlorpromazine in blocking a conditioned escape re-
sponse to harmful stimuli and a greater respo~_se specificity than chlor-
promazine. Tedeschi, Benigni, Elder, and Yeager (33) compared triflu-
operazine with five ~ther ph_enothiazines in measurement of minimal elec-
troshock seizure thresholds and spontaneous motor activity of mice. The 
drugs were administered orally to six groups of albino mice with five 
subjects in each group. The drug treated mice were shocked at 30, 60 0 
90, 1200 150v and 180 minutes after drug administration; and the charac-
ter of the seizures was recorded. All of the drugs tested produced sig-
nificant depre·ssion of. motor activity; their potency was ranked in the 
following descending order;trifluoperazine, chlorpromazine, prochlorper-
azine, promazine, promethazine, and mepazine. Chlorpromazine, promazine, 
. . 
mepazine, and piomethazine all produced significant decreases in minimal 
electroshock seizure thresh·olds (MET). Trifluoperazine and proclilorpera-
zine did not produce a significant decrease in MET. The data obtained 
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in this study indicated that a minimal electroshock seizure threshold-
lowering action is not a necessary property of effective. potent tran-
quilizing agents. 
Griffiths (7) used a total of 160 wild and domestic rats to measure 
resistance to stress of forced swinuning on Stelazine treatment. He found 
that none of the differences in swinuning times of the domestic rats could 
be attributed to the effect of Stelazine. Pre-treatment with the drug 
resulted in significantly longer swimning times, prior to exhaustion, 
for the wild Norway rats in comparison with rats that did not receive 
the drug. Griffiths pointed out the need for valid and reliable tech-
niques for quantifying the temperament of the animals in order to have 
a clearer understanding of the effects of Stelazine t.reatment on surviv-
al times of rats during forced swimming. Wild Cotton rats, group-housed 
in the laboratory for 30 days and treated with the drug, showed signif-
icantly shorter swinuning times than untreated subjects, but wild Norway 
rats, identically treated, showed significantly longer swinuning times 
than the untreated subjects. 
Numerous clinical studies using Stelazine have been reported. LeVann 
(13) used Stelazine for treating behavioral abnormalities in defective 
children. The drug was given to fourteen idiots, fourteen imbeciles~ 
and five morons. In each of the patients, rage reactions and anti-social 
behaviors were reduced. It was also found that the drug aided in break-
ing down conununications barriers that oftentimes exist between patients 
and members of the hospital team responsible for their care. 
A study dealing with aggression was conducted by Sexton (28). Tri-
fluoperazine was given to fourteen Negro female schizophrenics for a 
period of ten weeks. Seven of these patients were in constant restraint 
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for impulsive violence, destructiveness, and denudativeness. The other 
seven patients were apathetic and negativistic. Following Stelazine 
treatment, the seven unruly patients were permanently released from re-
straint. It was also observed that small doses of Stelazine often pro-
duced prompt initial improvement in some of the most disturbed patients. 
Petersen (23) found that Stelazine gave relief to a high percentage 
of depressed patients. He administered the drug to 167 mentally ill 
women exhibiting marked depression. The depression characteristically 
"lifted" after the first few days of drug treatment. Paranoid delusions 
frequently disappeared entirely or were lessened in intensity to such 
an extent that the patient no longer expressed them spontaneously. 
The beneficial effects of Stelazine in the treatment of depressed 
patients, as Petersen (23) demonstrated, is of tremendous importance in 
the treatment of mental illness. The characteristic treatment for de-
pression during the last generation has been with electroshock therapy 
(ECT). MacDonald and Watts (15) found that Stelazine gave better results 
or results equal to those of ECT or insulin coma treatment (ICT) for 
treating paranoid schizophrenics as well as patients who were markedly 
depressed and withdrawn. These investigators employed thirty male chronic 
paranoid schizophrenics, in an experiment that continued for nine months, 
as subjects in their evaluation of Stleazine as an anti-psychotic agent. 
The subjects 0 duration of illness ranged from two to fourteen years in 
the mental hospital. Before treatment, only four of the thirty patients 
were able to adjust :to social living in the hospital. After treatment, 
the other twenty-six patients, who could not adjust satisfactorily, were 
reduced to nine; twelve patients were able to adjust to social living 
in the hospital community; four patients were discharged from the hospital 
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and were able to adjust socially, but were unable to earn a living; and 
five were discharged from the hospital to engage in full time employment. 
Another group of twelve acutely ill psychotics, studied by Rudy, 
Rinaldi, Costa 0 Himwicho Tuteur, and Glotzer (25) showed even more im-
provement than that reported by MacDonald. Eight of these patients show-
ed a marked degree of improvement and six of them were discharged from 
the hospital and were able to care for themselves on the outside. 
Several investigators reported the drug's effectiveness in the 
treatment of patients in the chronic psychotic state. Tolan and Peppel 
(34) carried out an eight month investigation of the effects of Stelazine 
on twelve male and thirty-one female chronic patients. They found the 
drug to be very effective in the management of chronic catatonic schizo-
phrenia and chronic undifferentiated schizophrenia. These investigators 
reported that the drug activated lethargic, vegetative patients whose 
behavior was characterized by psychomotor retardation and apathy. 
Twenty males suffering from chronic schizophrenia were treated with 
Stelazine by Krawieki and Burns (10). Though the duration of Stelazine 
treatment or hospitalization was not indicated, five of the subjects 
were discharged to their home communities and full time employment; 
twelve subjects showed sufficient improvement to permit their transfer-
ence to open wards; and the other three subjects showed no improvement. 
Rudy and his associates (24) used the double blind technique to 
study two drug effectso trifluoperazine and triflupromazine. Each drug 
group was studied with a placebo treated control group. This investiga-
tion revealed that trifluoperazine was the more active phenothiazine de-
rivative. Its effective daily dosage (20-60 mg.) produced tranquiliza-
tion along with marked and varied improvements in alleviating psrchotic 
symptoms. 
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Kruse (11) tested the efficacy of Stelazine on llO chronic female 
schizophrenics over a period of two to eight months. These patients, 
whose ages averaged 37.4 years, had failed to benefit from any other 
form of treatment during their average of 5.3 years in the hospital. 
The most favorable response occurred early in treatment, usually between 
the first and fourth week. Twenty patients made an excellent response 
and were discharged from the hospital. Forty-eight patients made a 
good response and showed alleviation of most of their psychotic symptoms. 
BarsaQ Saunders 9 and Kline (1) conducted an experiment with thirty 
' ·~ \"" 
delusional and hallucinated chronic female psychotics. The majority of 
the patients were withdrawn, flat of affect, preoccupied, and disinter-
ested. At the enft of their five to seven month treatment perioda one 
patient was markedly improved and discharged from the hospital. Eight 
patients were moderately improved though not enough to permit a satis-
factory adjustment outside the hospital. Eight patients became more co-
operative, and the remaining thirteen patients showed no ch;mge. 
'".. 
Side effects have been observed iri most studies of the ef)fect,s of 
.1 
Stelazine upon the human organism. These extra-pyramidal symptoms were 
manifested most often in the form of Parkinsoni sm, dystonia, turbulence, 
akathi sia, and restlessness (5). Krawieki and Burns (10) stated that these 
distressing symptoms resulted in patients' perpetual feelings of rest-
lessne$s and weakness of the limbs, which was associated with insomnia 
at night. He found that he could control these symptoms fairly well 
with administration.s of artane. Tolan and Peppel (34) found that extra-
pyramidal symptoms are independent of dosage or duration of treatment 
and that they seem to depend on individual susceptibility to Stelazine. 
They also found extra-pyramidal syndromes to be more prevalent in females 
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than males. Davies (4) reported two cases of dystonic reaction in women, 
ages 18 and 28. The 28 year old patient developed dystonia only six 
hours after a second 5 mg. dose of Stela.zine. The 18 year old patient, 
also had a dystonic reaction following a second 5 mg. dose of the drug. 
When dosage was stopped, symptoms subsided within six hours in each 
case. Goldman (6) reported Parkinsonism occurring in not less than 35 
percent of the patients treated with Stelazine for one month or more. 
Kinross-Wright (9) reported that Parkinsonism occurred twice as fre-
quently in women than men under treatment with Stelazine. Nine cases 
of Parkinsonism developed in a group of twenty chronic schizophrenic 
males in an investigation by Markey (18), but all the side effects were 
reversible within a few days when medication was stopped or when dosage 
was sufficiently reduced. 
The Shipley-Hartford Intelligence Scale (3Q) and the Minnesota 
Multiphasic Personality Inventory (MMPI) {8) were both used in a study 
of the short term effects of chlorpromazine on psychiatric patients. (35). 
The Shipley-Hartford was used as an estimate of the intelligence of 
acute psychotic female patients newly admitted to the mental hospital. 
On the basis of intelligencev fifty-nine patients were given drug and 
placebo treatments for a period of one week. The MMPI was administered 
before and after treatment to measure response changes. All nine clin-
ical scales and the three validity scales were administered on pre and 
post treatment trials. Test-retest reliability coefficients 0 based on 
thirty-one cases, were computed for all twelve scales of the inventory. 
Reliability coeffJcients of • 86 were reported for scales lie {L) and 
psychasthenia (Pt) 0 but coefficients between. 75 and. 79 were reported 
for validity (F) 0 hypochondriasi s CHs), and schizophrenia (Sc) scales. 
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Coefficients for the remaining seven scales were less than. 75. 
Schmidt (27) administered the MMPI to 121 maladjusted army person-
nel at a United States Army base hospital and compared the test results 
with the diagnostic impressions of the army base psychiatrist. The 
testee was interviewed in a standard diagnostic interview when the psy-
chiatrist had no knowledge of the patient's test results. The principle 
investigator found the MMPI to make statistically significant distinc-
tions between neurotic and psychotic soldiers. Modlin (21) found that 
neuroticism was present when three scale scores, hypochondriasis (Hs), 
depression (D), and hysteria (Hy) were elevated on a given test profile. 
In contrast to this "neurotic triad," he further identified the "psy-
chotic triad" by the elevated scores on the paranoia (Pa), psychasthenia 
(Pt) 0 and schizophrenia (Sc) scales. His comparison of neurotic and 
psychotic scores provide a noteworthy clinical differentiation between 
neurotic and psychotic patients. 
In an investigation of the short term effects of chlorpromazine, 
Winter and Frederickson (35) used the double blind technique with drug 
and placebo groups. The Shipley-Hartford Intelligence Scale was em-
ployed for matching the groups on intelligence and the J\,lMPI was admin-
istered on pre-and post-treatment trials. A statistically significant 
change was found on MMPI performance. Steiper and Weiner (31) used 
the Shipley-Hartford and the MMPI to study the relationship between 
test scores and time spent in psychotherapy. These investigators found 
that length of time in psychotherapy did not correlate with improvement 
on test scores. Shipley and Burlingame (29, 30) standardized the test 
on 171 chronic psychotic state hospital cases, 203 neurotic and psy-
chotic private hospital cases, and 1046 normals. They found that the 
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ratio of abstract thinking ability to vocabulary level was an adequate 
index to degree of intellectual impairment. Reliability coefficients, 
based on 322 army recruits, were .87 for vocabulary, .89 for abstract 
reasoningv and .92 for the combined scales. 
The HAS consists of three groups of scores that refer to different 
types of behavior. The Group I score relates to communication and inter-
personal relations; the Group II score relates to care of self and so-
cial responsibility; and the Group III score relates to work, activities, 
and recreation (20). Group scores are the basic units of measurement on 
the HAS. Lorr (14) reported that the Hospital Adjustment,Scale (HAS) is 
an ingeniousv carefully constructed device for evaluating the behavior 
of hospital patients. He found that it distinguished between patients 
showing improvement in adjustment and approaching discharge and the dis-
turbed or chronic hospital residents. The procedure for completing this 
rating scale typically requires from 10 to 15 minutes and can be done by 
the ward nurse who is best acquainted with the patients (19). Stilson 
(32) found a reliability of • 79 for the HAS when test-retest scores were 
obtained two weeks apart by student nurse raters. 
The Malamud-Sands Psychiatric Ra:ting Scale (17) provides a single 
score as an index to degree of pathology •. To test the validity of this 
rating scalev six pairs of psychiatrists did several ratings on a total 
of 26 patients. On 180 paired ratings, the correlation coefficient for 
the six pairs of raters was .92. 
CHAPTER II 
STATEMENT OF PROBLEM 
Previous procedures described in the literature concerned with eval-
uating the influence of Stelazine on the behavior of psychotics have been 
restricted to generalizations relative to the employment of subjective 
measures to determine the amount of improvement shown by patients. Hos-
pital patients who are treatedv discharged, and not re-admitted provide 
the best criterion for judging the effectiveness of the drug. Howeverv 
when patients are judged to be markedly improved, somewhat improvedv or 
mildly regressedv with no further quantification, the true effects of 
the drug treatment are clouded. 
There appears to be a critical need for the development of quanti-
tative methods in determining the influence of tranquilizing drugs on 
behaviors of organisms. This need has been partially alleviated by the 
study of Tedeschiv et al. (33) concerned with the effects of Stelazine 
on electroconvulsive shock thresholds and spontaneous motor activity of 
mice.· Griffiths (7) has also presented quantitative data concerned with 
the effects of Stelazine on resistance to exhaustion of forced swimming 
of wild and domestic rats. Madgwick 06) found a significant increase 
in speed of performance on the Modified Peg Board !'est of motor speed 
and a significant increase in scores on the Knox Cube Attention level 
test in a study of the effects of Stelazine on chronic psychotic pa-
tients. Lehman and Knight (12) have reported empirical measures on a 
9 
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series of psychophysiological tests administered to normal humans prior 
to and following a single treatment with Stelazine. 
In the present studye four psychological tests were given to two 
groups of chronic psychotics; one group maintained on Stelazine, the 
other on placebo. The duration of the treatments was 66 days and the 
problem was to determine whether the drug treated group would show sig-
nificant improvement in hospital adjustment as measured by the Hospital 
Adjustment Scale (14v 199 20, 32), in personality organization as meas-
ured by the Malamud-Sands Psychiatric Rating Scale (17) and the Minne-
sota IIultiphasic Personality Inventory (8, 21, 27), and in intelligence 
in terms of the Shipley-Hartford Intelligence Scale (29, 30). 
CHAPTER III 
METHODS AND PROCEDURE 
A. General Methodology 
The present study was conducted in order to ascertain whether pa-
tients treated with Stelazine for a period of 66 days would improve sig-
nificantly over a matched group of patients treated with a placebo for 
the same period of time. 
A significant improvement is defined as a difference at the 5 per-
cent level of confidence or less between the post-treatment tests and 
ratings of the two treatment groups. This level of confidence was arbi-
trarily selected as the criterion for rejecting the null hypothesis of 
no difference between the groups. 
Independent Variable 
Stelazine was administered orally each day to the patients in the 
Experimental Group throughout the duration of the study. The dosage was 
carefully titrated for each patient individually by the medical advisor 
in order to achieve maximum benefit with the lowest possible dosage. 
Dependent Variables 
Four dependent variables were measured in the study. Adjustment to 
hospital living conditions, observed in the patients' overt behavior, 
was rated at three periods on the Hospital Adjustment Scale. Changes in 
11 
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intellectual functioning were measured immediately before and immediat-
ely after Stelazine therapy by the Shipley-Hartford Intelligence Scale. 
Fluctuations in personality organization were rated at three periods on 
the Malamud-Sands Psychiatric Rating Scale.. The Minnesota Mul tiphasic 
Personality Inventory (MMPI) was also administered before and after drug 
therapy to reflect changes in personality structure. Greater pathology 
is indicated by higher scores on the Malamud-Sands Psychiatric Rating 
Scale and the MMPio and by lower scores on the Hospital Adjustment Scale 
and Shipley-Hartford Intelligence Scale. 
B. Subjects 
A homogeneous sample of patients was selected from the female chronic 
wards at the Eastern Oklahoma State Hospital. The sample was divided in-
to two groups of 2·4 patients by random assignment of patients to Experi-
mental and Control Groups. 
Criteria for Selection 
1. .Aw!. The age range of the subjects in _the study was from thirty 
io forty nine years. The mean age for· the.se patients was 41. 5 years. 
· 2. ~. Only female patients were used as subjects. 
3. ·Physjcal HeaHh. Subjects in the present investigation were free 
from neurological impairment and relatively .free from other chronic or 
acute physical disorders. Mental defectives and patients suffering from 
organic involvement in their psychosis were not included in the study. 
4. Functional Psychotic Disordsrs, Chronic. Subjects were patients 
who had been diagnosed as chronic psychotics and who had been ·retained on 
a chronic ward for fifteen months or longer. The average length of hos-
pitalization for all subjects was 8.6 years. 
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5. Behavior. The subjects were withdrawn, apathetic, and lethargic, 
and were mostly "sitters" on the wards. This group of patients had no 
work assignments. 
6. Preselection Testing. Only those patients who could demonstrate 
the ability to read, und~rstand, and make decisions on a group of 30 state-
ments were considered for this study. 
C. Procedure 
Preselection Interviews 
A homogeneous sample of 48 patients was selected as subjects from 
all the chronic psychotic female wards, located in the same building, at 
the Eastern State Hospital. All the patients on the chronic wards who 
met the first four criteria for selection were given an intensive diag-
nostic interview. The interviews were conducted in the same manner as 
regular patient staff meetings. Each patient's hospital record was care-
fully reviewed before the patient was called to appear. The persons tak-
ing part in the interviews were a psychiatrist of diplomate status, the 
ward physician, a registered nurse who had completed psychiatric train-
ing, and a clinical psychologist. Each person assisting with the inter-
views had observed the patients' behaviors in different situations, which 
were usually unknown to the other three persons on the interviewing team. 
Each person, therefore, was able to make contributions to the interviews 
by being in possession of information that was unique to his own profes-
sional role. The purpose of the preselection interviews was to select 
only those patients who met the fifth criterion for selection •. About 
160 patients were interviewed on the same day. 
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Preselection Testing 
Sixty-nine patients. who met the first five criteria were adminis-
tered a preselection test. The test was made up of 30 items from the 
M.MPI which were statements of behavior and attitudes that the patients 
were required to answer as either true or false as it applied to them-
selves. The purpose of the preselection test was to eliminate the pa-
tients who would be unable to participate in periodic psychological 
testing. Twenty-one patients were eliminated because of their inability 
to read 0 understand the meaning of the statements, or because of their 
inability to determine whether the statements had reference to their own 
behavior. Following this final step in the preselection procedurer the 
remaining 48 patients were taken off of all tranquilizer medication for 
a period of 21 days prior to the beginning of their Stelazine therapy. 
Random Selection of Experimental and Control Groups 
The random selection of Experimental and Control subjects was achiev-
ed by the following method: first, the names of all 48 patients were 
typed on small cards of one and one-half inches in length and one inch 
in ~idth. The diagnostic classification was typed directly beneath the 
patient vs name. Second, the cards were placed in a small box which was 
eight inches long 0 four inches wide, and three inches deep and the box 
was shaken for thorough mixing of the cards. Third, a neutral person, 
who was blindfolded 0 drew one card at a time from the box and a secretary 
recorded the names alternately on the Experimental and Control lists. 
The remaining cards in the box were thoroughly mixed following each 
draw. Since Stelazine is purportedly most effective with patients of 
the Schizophrenic Reaction, Catatonic Type, randomization was done first 
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with patients of that classification. This stratified randomization pro-
vided each group with an equal representation of Catatonic subjects. The 
remaining names we.re assigned in the same random fashion. The identity 
of the Experimental and Control subjects was known only by the medical 
advisor and the secretary who typed the lists. The Experimental Group 
received Stelazine tablets daily and the Control Group received daily ad-
ministrations of the placebo throughout the entire study. 
Group Psychotherapy 
The subjects in this investigation also participated in group psy-
chotherapy throughout the period of Stelazine therapy. The combined· 
treatment groups were divided into four equal therapy groups. The same 
random procedure of assigning subjects to Experimental and Control Groups 
was used in assigning subjects to the four therapy groups. However, 
three changes were made in group therapy assignments to provide greater 
homogeneity of the individual groups and to facilitate communicative in-
teraction within the groups. Each therapy group met one session per week 
on their scheduled day. Group therapy was scheduled on Tuesday, Wednes-
day, Thursday 0 and Friday; the therapy sessions began promptly at 8:15 
A. M. and ended promptly at 9:15 A. M. 
An experienced group therapy observer met each therapy session and 
took detailed notes to provide a ttrunning account" of each session. The 
primary role of the observer was that of an unobtrusive secretaryv who 
refrained from participating in any form of group interaction. After 
each therapy session, the observer and therapist met for approximately 
30 minutes in order to evaluate and summarize the data. The summaries 
of each meeting were dictated and typed for a permanent record. 
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The role of the therapist in the group sessions was primarily non-
directive and supportive. The patients instead of the therapist played 
the central role in their attempts to achieve resolution to emotional 
disturbances. The therapist refrained from making any suggestions to 
the patients about the nature of their problems, and no advice was given 
or direct.ive methods employed to help patients with emotional problems; 
howeverv patient.s were encourag~d to talk out problems of a conflicting 
nature. 
Testing Schedule and Test Instruments 
The four tests measuring the dependent variables were given in the 
following order: · the first testing was completed two days prior to the 
beginning of Stelazine therapy and three days prior to the beginning of 
group therapy. Each subject was rated on the Hospital Adjustment Scale 
by the ward nurse and attendants; the Shipley-Hartford Intelligence Scale 
and the MP.WI were administered during two testing periods to 24 subjects 
at each period; and ratings on all the subjects were made by two staff 
physicians using the Malamud-Sands Psychiatric Rating Scale. The first 
testing was completed in a period of two days and these results supplied 
the necessary pre-treatment test data for the study. All the subjects 
were rated again on the Hospital Adjustment Scale and the Malamud-Sands 
Psychiatric Rating Scale after the first 21 days of drug therapy in or9er 
to de~ermine the extent of the quick-acting aspects of Stelazine. The 
time required for the completion of these ratings was two days. When 
the study was terminated after a p·eriod of 66 days, all four measuring 
instruments were again employed over another two day period to provfde 
the neces.sary post-treatment test data for the study. The procedure 
used for testing and completion of rating scales was held constant 
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throughout the studyi the same persons used the same measuring instruments 
after each appropriate time interval. 
D. Experimental Controls 
Two Matched Groups of Subjects 
Two matched groups of subjects were obtained by careful selection 
of subjects on the basis of possession of characteristics that are simi-
lar and equal for the purposes of this study. Matched groups were used 
in an attempt to exclude all extraneous variables possible in determining 
the relationship between independent and dependent variables. 
Previous Medication 
The medical advisor for the project gave written orders to the ward 
nurse for all project patients' tranquilizer medication to be discontinued 
for the period of 21 days prior to Stelazine therapy. The only medicines 
permitted were aspirin tablets and laxatives. These orders were given 
as an effort to control for the influence of prior tranquilizer medica-
tion. 
Drug and No Drug Treatments 
The method of randomization assured the probability of .50 for the 
placement of each patient in the drug or no drug treatment group. 
Double Blind Method 
Through the medical advisor's refusal to disclose the identity of 
Experimental or Control subjects to any person, neither subjects nor 
persons assisting with the project could determine with certainty the 
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identity of drug or no drug patients. The subjects il1 the study were 
told that the drug has differential effects upon people. 
The double blind method was.successful in eliminating biasing ef-
fects that might have occurred in rating scale judgements as well as 
patient-therapist relationships in group therapy. 
Control of Dosage 
Written orders were given by the medical advisor to the ward nurse 
before dosage was increased or decreased for any subject. This control 
of medication ruled out the potential variable of over dosage and under 
dosage. When subjects refused the medicine, it was given in liquid form 
in fruit juice or by intramuscular injection. These controls of dosage 
were an aid in achieving the maximum therapeutic effects of Stelazine. 
Three Testing Trials 
The three testing trials in the study, which were given before 
treatment~ after 21 days of treatment, and after 66 days of treatment, 
provided methods of determining the degree of changes taking place after 
those intervals of time. 
Group Therapy Controls 
(a) The Role of the Therapist. The non-directive method was em-
ployed and held relatively constant for all four therapy groups. By 
keeping therapy on the "client centered" level, the opportunity was made 
available for subjects to ventilate their feelings and verbalize anxiet-
ies that were apparently elevated as a function of the energizing effects 
of Stelazine. Adhering to this method of psychotherapy also placed 
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controls on the therapist and helped to eliminate the factor of bias. 
(b) The Role of the Observer. The role of the observer in group 
therapy was that of a secretary who took detailed notes on subjects~ 
verbalizations. Small group interactions were also noted. 
CHAPTER IV 
RESULTS 
In order to study the psychological effects of Stelazine on chronic 
psychotic patients after specified periods of treatment, the standard 
errors of differences between means were computed for each of the three 
testing trials. The mean basic unit scores, divided by a constant of 







__ TABLE I 
AVERAGE HOSPITAL ADJUSTMENT SCALE SCORES OF STELAZINE 
AND PLACEBO TREATED PATIENTS 
Tr~gtm~nt1 
Placebo Stelazine 
7. 6 7.5* 
7. 7 8.5 
7. 6 8.8* 





* Necessary ·difference between trials I and III= 1.02 (p<.05). 
A significant difference between scores made on trial I. (prior to drug 
treatment) and those shown for trial III- (after drug treatment), for 
the Stelazine treated subjects, indicates that the drug had a beneficial 
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effect on the behavior of these chronic psychotic patients (p<.05). 
However, a comparison of_scores obtained during the pre-treatment period 
with those obtained after 21 days of drug treatment, indicated that the 
difference in scores merely approached significance for the Stelazine 
patients on ~hort term trea_tment • 
• 
.Mean Hospital Adjustment Scale scores, for chronic psychotic pa-
tients on Stelazine an_d placebo treatments, are presented in Figure l, 
which shows the changes in behavior that were observable prior to treat-
ment, during· treatment, and follo_wing treatment. A statistical analysis 
of the Hospital Adjustment Scale scores obtained by the subject~ in both 
treatment groups, appears in Table I of Appendix A. This analysis, ba-
sed on scores obtained on trials II and III (second and third adminis-
trations of the test), demonstrated a significant difference in favor . . 
of the Stelazine treated patients after 66 days of drug treatment (F = 
4. 40, p <· 05). 
The mean scores for trials I, II, and III on the Malamud-Sands Psy-
chiatric Rating Scale are presented in Table II. An analysis of the 
treatment data (trials II and III) appears in Table II of Appendix B, 
which shows that the Stelazine treated paiients failed to demonstrate 
significant improvement over the placebo ireated patients on ratings of 
personality functions. CF= 1.03, p >.05). The mean Malamud-Sands Psy-
chiatric Rating Scale scores for trials I, II, and III are presented for 
Stelazine and placebo treated patients in.Figure 2, which shows the 
placebo treated patients to be slightly superior to the drug treated pa-
tients on trial III. The analysis indicated that the observed differ-
ence was not statistically significant. The sums of scores -and means 
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TRIA,LS 
Figure 1. Mean Hospital Adjustment Scale basic unit scores for chronic 
psychotic patients on Stelazine and pla~ebo treatmentsk 
Trial I is a pre-treatment rating; trials II and III were 
administered after 21 and 66 days of treatment, respectively. 
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rated on the Malamud-Sands Psychiatric Rating Scale for trial III are 
presented in Table III. Lower scores, indicating less pathology for the 
placebo patients, were found on the following functions: motor activity, 
socialization, speech, mood, affect, and feeling. 
TABLE II 
EFFECTS OF STELAZINE ON MEAN MALAMUD-SANDS 
PSYCHIATRIC RATING SCALE SCORES 
Treatment Grougs 
Trials Experimental Control 
Pre-Treatment 
Trial I-scores 16.12 16.57 
During Treatment 
Trial II scores 15.62 15.28 
Pg§ t-Ir~ ~:tmsn:1 t 
Trial III scores 15.31 12.57 






Neurotic and psychotic triad difference standard scores between the 
pre- and post~treatment testing of Stelazine and placebo treated pa-
tients were obtained from the Minnesota Multiphasic Personality Inven-
tory (M.MPI). The sums of the differences of standard· scores for hypo-
chondriasis (Hs), depression (D), and hysteria (Hy) of the neurotic tri-
ad are presented for the drug and control groups in Table IV. An analy-
sis of the difference scores on the neurotic triad scales which appears 
in Table III of Appendix C, fails to show any superiority for Stelazine 
treated subjects on these measures. 
17.0 
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III 
Mean Malamud-Sands Psychiatric Rating Scale scores for 
chronic psychotic patients on Stelazine and placebo 
treatments. Trial l is a pre-treatment rating; trials 




SUMS OF SCORES AND MEANS FOR 15 FUNCTIONS OF BEHAVIOR ON 
THE MALAMUD-SANDS PSYCHIATRIC RATING 
SCALE FOR TRIAL III 
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Function Stelazine Patients Placebo Patients 
Appearance 4 6 
Motor Activity 15 8 
.Mimetic Expression 12 9 
Responsibity 9 9 
Hostility Reaction 7 6 
Socialization 18 9 
Attention 6 6 
Speech 13 4 
Mood 13 7 
Affect 19 10 
Feeling 20 6 
Perc~ption 11 6 
Thought Processes 18 18 
Subjective Reorganization 20 20 
Insight 60 52 
Sum 245 176 
Mean 15.31 12.57 
TABLE IV 
NEUROTIC TRIAD DIFFER~CE SCORES BETWE~ PRE-AND POST-TREATMENT 
TESTING ON THE MMPI (PUJS A CONSTANT OF 8.00). 




































The sums of the differences of standard scores for paranoia (Pa) 1. 
psychasthenia (Pt), and schizophrenia (Sc) of the psychotic triad are 
presented for the Stelazine and placebo treated patients in Table V. 
The analysis of the difference scores on the psychotic triad scales ap-
pears in Table IV of Appendix C, and fails to indicate any significant 
effect of the drug on these measures of behavior. 
Differences between pre- and post-treatment raw scores on the 
Shipley-Hartford Intelligence Scale vocabulary and abstract reasoning 
tests are presented in Tables VI and VII. An analysis of the pre- and 
post-treatment vocabulary difference scores shown in Table V of Appendix 
D indicates that the Stelazine treated patients failed to show a sta-
tistically significant imprQvement over the placebo treated patients. 
The analysis of pre- and post-treatment abstract reasoning difference 
scores, presented in Table VI of Appendix D, shows that the drug treated 
group failed to demonstrate a significant improvement over the placebo 
treated group. 
TABLE V 
PSYCHOTIC TRIAD DIFFERENCE SCORES BETWEEN PRE-AND POST...!fREATMENT 
TESTING CN THE MMPI (PUJS A CONSTANT OF 25. 00) , 




































VOCABULARY DIFFERENCES IN RAW SCORES ON THE SHIPLEY-HARTFORD 
INTELLIGENCE SCALE (PLUS A CONSTANT OF 8.00) 





















ABSTRACT REASCNING DIFFERENCES IN RAW SCORES ON THE 
SHIPLEY-HARTFORD INTELLIGENCE SCALE 
(PUJS A CONSTANT OF 2. 00) 





































From the total group of 48 subjects participating at the start of 
the present study, 14 were eliminated due to additional medications in-
troduced by the medical department. Four other subjects were eliminat-
ed prior to the beginning of the treatment period because of behavioral 
disturbances that prevented their participation. 
It was supposed that the residu?l effects of previous medication, 
administered over a long period of time to the patients prior to their 
participation as subjects in this study, rendered it difficult for some 
of the patients to be maintained on Stelazine alone and even more dif-
ficult for others to be maintained on a placebo. The fact that. more of 
the control than experimental subjects were lost from the study seems 
to infer that Stelazine has tranquilizing as well as stimulating prop-
erties. 
Statistical analyses of test results obtained in the present study 
indicate that Stelazine is a very effective agent for the treatment of 
chronic psychotics, when administered to markedly withdrawn, lethargico 
and apathetic patients. A statistically significant difference (p <· 05) 
in favor of the Stelazine group on Hospital Adjustment Scale scores in-
dicated that the drug treated patients were responding to the environ-
ment and social milieu of the hospital. 
By the end of the first two weeks in the study, the occupational 
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therap.ist had assigned work duties to all of the subjects in the pro-
ject. Five Stelazine patients did not continue with their work assign-
ments, because·two of them were discharged to their homes and self sup-
porting employment, one patient was relieved from work duties because 
of Parkinsonism, one patient fell down stairs and fractured a femur, 
and the other drug treated patient became disturbed and could not con-
tinue with he.r work assignment. Five placebo treated patients failed 
to continue their work assignments because four patients were too dis-
turbed and disruptive to do the work, and one placebo ~reated patient 
was transferred to a nursing home, which is a type of "half-way house" 
to being discharged. It is also noted that none of the patients who re-
quired, extraneous medication were considered for discharge. 
The chief value of the Malamud-Sands Psychiatric Rating Scale in 
the present study was demonstrated by its use in detecting and quanti-
fying the excitatory effects of Stelazine in the drug treated subjects. 
1 .• 
:., 
The use of this scale would appear to impose a bias against the effec-
tiveness of Stelazine, since the energizing effects of the drug elevated 
scores of some of the scales of behavior functions. However, this in-
strument proved to be valid for discriminating between patients who were 
drug treated and those who were treated with the placebo. so·me of the 
elevated scores for the drug treated patients were found on functions 
of motor activity, which showed restlessness or excitability; socializa-
tion, which was obse.rved to be outreaching or meddlesome; speech, which 
was usually overproductive; mood, which appeared to be enthusiastic or 
euphoric; and feeling, which was usually tense or anxious. 
Extra-pyradmidal symptoms, .or side effects, were also reported from 
the psychiatric interviews. There appeared to be three unmistakable 
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cases of Parkinsonism. The most interesting case was one patient who 
appeared to have all the symptoms of incipient Parkinsons Disease, but 
this patient was a subject in the placebo treatment group. She referred 
to her symptoms as being "like those of the other girls." Her symptoms 
disappeared when the Stelazine dosage of the Parkinsonism cases was re-
duced. 
Stelazine appears to be a very potent and quick acting agent for 
the treatment of chronic psychotics. In only 66 days of Stelazine treat-
ment, chronic psychotic patients, who· had averaged over 8 years in the 
mental hospital.-made a statistically significant improvement in ad-
justment to the hospital living conditions; but when differences in Hos-
pital Adjustment S~ale scores obtained prior to drug treatment and after 
21 days of drug treatment were analyzed, the degree of improvement fail-
ed to reach signifjcance by only .02. This could have been a result in 
the method of handling basic unit scores, which were divided by a con-
stant of 10 and rounded to the nearest whole number, Some precisi.on was 
undoubtedly lost with this method, 
The differences between pre-and post-testing scores obtained on the 
Minnesota Mul tiphasic Personality Inventory were non-significant for the 
experimental group and for the control group, when raw scale scores were 
converted into standard scores and grouped on the neurotic triad (scales 
Hs, D, and Hy) , and on psychotic triad (scales Pa, Pt, and Sc). These 
two triads, composed of six of the most important diagnostic scales, 
would be more than adequate to reflect any real changes in personality 
structure as a function of the administration of Stelazine to chronic 
psychotics. 
When differences were obtained between pre- and post-treatment scores 
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on the vocabulary and abstract reasoning tests of the Shipley-Hartford 
Intelligence Scale, the non-significant result obtained by the analysis 
of these difference scores probabl.Y occurred as a function of a possible 
suppression effect on higher neural centers on the Central Nervous Sys-
tern. 
Stelazine apparently has a cumulative effect upon human functioning 
and behavior. This may be an adequate explanation for the difference 
in statistical results obtained by the drug treated patients on Hospital 
Adjustment Scale scores when pre-treatment test results were compared 
with those obtained after 21 days of drug treatment and with thos.e ob-
tained after 66 days of drug treatment. A cumulative effect of the drug 
would account for the obtained statistical significance Cp <.05} in the 
second comparison as well as '1:he lack of significance found in the first 
comparison. These results suggest tffat another ·study of the psychologi-
cal effects of Stelazine, conducted in a similar manner but free of the 
confounding effects of extraneous medication, might possibly find that 
the other three test instruments used in this_ study would obtain statis-
- tical s_iggificance in favor of Stelazine treated patients. 
It was felt that several demonstrations of aggressive behavior by 
patients who became disturbed were the results of the· energizing ef-
fects of Stelazine. After the identity of the experimental and control 
patients was made known, it was apparent that this hypothesis was incor-
rect. Only four aggressive demonstrations were observed in ·two patients 
in the drug treated group, but 11 explosive acts were listed for eight 
subjects in the placebo group. This fact supplies further· evidence that 
Stelazine has tranquilizing .effects as well as stimulating effects. 
Bowen (3) reported that Stelazine is the most potent phenothiazine 
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derivative yet developed~ and that is is 10 times more active than chlor-
promazine. This experimental evidence leaves little room for doubt that 
Ste lazine is a tranquilizer. Ch lorpromazine apparently inhibits the 
chemoreceptors in the diencephalon, which seems to have an effect on 
many psychic and physiological processes integrated in the central and 
autonomic nervous systems. Griffiths' (7) hypothesis that similar ef-
fects occur when Stelazine is administered to rats, seems plausible. 
Apparently Stelazine activates the motor areas of the central nervous 
system, yet has an inhibiting effect on higher neural centers. This 
seems adequate to account for the obtained results'of the four psycho-
logical tests administered to measure the effects of Stelazine in the 
present study. 
CHAPTER VI 
SUMMARY AND CONCLUSIOOS 
The psychological effects of Stelazine on chronic psychotic hos-
pital patients were studied for a period of 66 days by using two match-
ed groups of subjectsi one treated with the drug and the other treated 
with a placebo. All subjects in both treatment groups were rated on 
the Hospital Adjustment. Scale (HAS) and the Malamud-Sands Psychiatric 
Rating Scale prior to treatment, after 21 days of treatment, and after 
66 days of treatment. The Minnesota Mul tiphasic Personality Inventory 
(MMPI) and the Shipley-Hartford Intelligence Scale were administered 
prior to treatment and after 66 days of treatment. 
Results of the HAS scores indicated that the drug treated subjects 
improved significantly in their adjustments to hospital living condi-
tioll's when treated with Stelazine for the 66 days duration of the study 
(p.<.05). Improvements in drug patients approached significance after 
21 days of Stelazine treatment. When HAS scores for the drug and place-
bo treated patients were compared, a significant improvement was observ-
ed in favor of the drug treated group (p <• 05). 
The Malamud-Sands Psychiatric Rating Scale did not reflect signifi-
_cant behavioral differences between drug and placebo treated patients; 
however, this scale proved to be a valid instrument in the detection of 
the energizing effects of Ste.lazine. Scores between prior to treatment 
and following treatment differences in performance on the MMPI and 
Shipley-Hartford Intelligenc·e Scale for both treatment groups did not 
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provide statistically significant results between changes in behavior 
on either test for either treatment group. 
On the basis of psychological data made available in the present 
study, the following conclusions seem warranted: 
1 •. The only response measure used with sufficient sensitivity 
to detect beneficial behavioral effects of Stelazine treat-
ment was the Hospital Adjustment Scale. 
2. It is suggested that a similar study, using a larger number 
of subject'su more uniform controls of medication, and pos-
sibly other response measures, would possibly provide more 
valid indications of the effectiveness of Stelazine as an 
agent for the treatment of chronic psychotic hospital pat-
ients-. 
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APPENDIX TABLE II 
EFFECTS OF STELAZINE ON MALAMUD-SANDS PSYCHIATRIC 






















30. 81 · 1. 78 
21. 54 1. 24 
17.29 Error 









APPENDIX TABIE III 
ANALYSIS Of VARIANCE OF DIFFERENCES BETWEEN PRE- AND POS'.1:-TREATMENT 
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APPENDIX TABLE V 
ANALYSIS OF VARIANCE OF DIFFERENCES BETWEEN PRE- AND POS'.F-TREAT8T 
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